Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Luye Pharma Group's share price for the quarter that ended in Dec. 2023 was HK$3.73. Luye Pharma Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 3,762 Mil. Therefore, Luye Pharma Group's market cap for the quarter that ended in Dec. 2023 was HK$14,031 Mil.
Luye Pharma Group's quarterly market cap
declined
from Dec. 2022 (HK$12,582 Mil) to Jun. 2023 (HK$12,451 Mil) but then
increased
from Jun. 2023 (HK$12,451 Mil) to Dec. 2023 (HK$14,031 Mil).
Luye Pharma Group's annual market cap
increased
from Dec. 2021 (HK$12,208 Mil) to Dec. 2022 (HK$12,582 Mil) and
increased
from Dec. 2022 (HK$12,582 Mil) to Dec. 2023 (HK$14,031 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Luye Pharma Group's Enterprise Value for Today is HK$11,367 Mil.
Luye Pharma Group Market Cap Historical Data
The historical data trend for Luye Pharma Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Luye Pharma Group's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's Market Cap falls into.
Luye Pharma Group Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Luye Pharma Group's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (HKSE:02186) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Luye Pharma Group Market Cap Related Terms
Thank you for viewing the detailed overview of Luye Pharma Group's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Luye Pharma Group (HKSE:02186) Business Description
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02186 has been successfully added to your 